z-logo
Premium
Phannacokinetics of Intravenous Immunoglobulin in Neonates
Author(s) -
Weisman Leonard E.,
Fischer Gerald W,
Marinelli Philip,
Hemming Val G.,
Pierce John R.,
Golden Stephen M.,
Peck Carl C.
Publication year - 1989
Publication title -
vox sanguinis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.68
H-Index - 83
eISSN - 1423-0410
pISSN - 0042-9007
DOI - 10.1111/j.1423-0410.1989.tb00836.x
Subject(s) - pharmacokinetics , antibiotics , medicine , antibody , dosing , sepsis , neonatal sepsis , streptococcus , toxicity , pharmacology , immunology , gastroenterology , biology , microbiology and biotechnology , bacteria , genetics
. Intravenous immunoglobulin (IVIG) may be a therapeutic adjunct to antibiotic treatment of neonatal infections. We examined the pharmacokinetics and safety of IVIG in human neonates. Thirty neonates with suspected sepsis were randomly assigned either to a treatment (receiving either 250, 500, or 1,000 mg/kg of IVIG plus antibiotics) or control (antibiotics alone) group. The 500 mg/kg dose produced a rise in total IgG for >8 and in group B streptococcus (GBS) type‐specific IgG for > 4–14 days. The type‐specific antibody elevation varied with the amount of pathogen‐specific antibody and dose of IVIG. Pharmacokinetic analysis suggests a Vd ss of 42ml/kg, Cl of 3.0ml/kg/day, a biphasic elimination curve, and a terminal elimination half‐life of 24.2 days. No toxicity was observed. These data may be valuable in determining optimal dosing schedules for IVIG in treating or preventing neonatal infections.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here